Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.47 |
| ▸ | CHKA | P35790 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30059168 | 1.00 | SMN1; SMN2 (0.62) | SMN1; SMN2HTR1ADRD2HTR2AKDM4E | |
| SCHEMBL2952071 | 0.88 | SMN1; SMN2 (0.57) | SMN1; SMN2KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL16054808 | 0.88 | ALDH1A1 (0.53) | SMN1; SMN2HTR1ADRD2HTR2AKDM4E | |
| SCHEMBL28088851 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL3114233 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4EALDH1A1POLBMAPT | |
| SCHEMBL3117941 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL3103670 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL4849323 | 0.87 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL16054521 | 0.87 | KDM4E (0.52) | SMN1; SMN2HTR1ADRD2HTR2AKDM4E | |
| Hydrochloric Acid SCHEMBL3102720 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2KDM4EALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112047932-A | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2020-12-08 | — | — | CN | disclosed |
| CN-106795152-B | Protein kinase inhibitors | 安斯达尔生物技术有限责任公司 | 2020-01-31 | — | — | CN | disclosed |
| EP-2880038-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| US-9776988-B2 | Pyrazolylbenzo[d]imidazole derivatives | CELON PHARMA S.A. (PL) | 2017-10-03 | — | — | US | disclosed |
| CN-106795152-A | Protein kinase inhibitors | 安斯达尔生物技术有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-2395000-A1 | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases | Astex Therapeutics Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| EP-1968579-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| EP-1833819-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | SMN1; SMN2 3461/4885HTR1A 3270/4885DRD2 4104/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | SMN1; SMN2 2569/4885HTR1A 2967/4885DRD2 3451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.